ClinicalTrials.gg
RecruitingNCT06521671Updated Jan 27, 2026

Evaluation of Fracture Migration After Internal Fixation of Femoral Neck Fractures in Younger Adults: A Clinical RCT Using RSA

An interventional study of Dynaloc implant and Cannulated cancellous screws in Femoral Neck Fractures, Internal Fixation; Complications and Hip Fractures, sponsored by Odense University Hospital. Recruiting at 4 sites in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-01-27.

Sponsored by Odense University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The goal of the clinical trial is to compare different surgical methods for internal fixation of femoral neck fractures in younger adults.

The main question it aims to answer is:

Is internal fixation with the novel implant consisting of three angle stable screws locked together by a plate equal to internal fixation with cancellous screws or a sliding hip screw in younger adults under 65 years of age in terms of fracture migration?

The study will examine how stable the fracture remains during healing. This will be measured by assessing how much the fracture moves after surgery using a highly precise imaging method called radiostereometric analysis (RSA). The study will also record complications and evaluate pain, health related quality of life, and hip function over time.

The participants will be treated with either a novel angle stable implant (Dynaloc), cannulated cancellous screws or sliding hip screw and followed up at 6 weeks, 12 weeks, 6 months and 12 months. Recruitment will continue until 75 participants, 25 in each group, have completed the 12-week follow-up for the primary outcome.

Read the detailed description

Objective The overall purpose of the study is to assess internal fixation methods for femoral neck fractures in adults under 65 years of age. The primary objective is to compare fracture migration following internal fixation with a novel angle-stable implant (Dynaloc, Swemac) and cannulated cancellous screws (CCS), using fracture migration as the primary outcome.

In addition, a cohort of patients treated with a sliding hip screw (SHS) as part of standard care will be included to provide an additional basis for comparison.

Dynaloc, CCS, and SHS are all CE-marked medical devices used in accordance with the manufacturers' intended use.

Trial design The study is designed as a multicentre, single-blinded randomised controlled trial with radiostereometric analysis (RSA), including an additional prospective cohort.

Patients undergoing internal fixation with Dynaloc or CCS will be randomised, while patients treated with a sliding hip screw will be followed as a separate cohort using the same imaging and follow-up protocol.

Interventions Eligible patients will be randomised to internal fixation with either three CCS or the Dynaloc implant.

Patients who do not undergo randomisation and are treated with SHS as standard care may be included in a prospective cohort and followed according to the study protocol.

All surgical procedures will be performed according to the manufacturers' surgical techniques and instructions for use.

Sample size calculation The primary outcome is shortening of the femoral neck at 12 weeks. A clinically relevant difference is defined as femoral neck shortening greater than 5 mm. Femoral neck shortening in patients treated with CCS is expected to be 5.3 mm (SD 4.5 mm) at 6 weeks, and no further clinically relevant shortening is expected between 6 and 12 weeks.

Using a power of 0.9, a significance level of 0.05, and assuming a maximum femoral neck shortening of 1 mm in the Dynaloc group compared with 5.3 mm (SD 4.5 mm) in the CCS group, a total sample size of 50 randomised patients (25 per group) is required.

In addition, a cohort of 25 patients treated with a sliding hip screw will be included for comparative purposes.

Inclusion will continue until all 50 randomised patients and all 25 cohort patients have completed the 12-week follow-up for the primary outcome. Due to the rarity of femoral neck fractures in this age group, up to approximately 20% additional patients may be included to ensure complete 12-week follow-up.

Randomization/allocation After informed consent is obtained, eligible patients will be enrolled and entered into an electronic database. Patients will be randomised to either CCS or Dynaloc using block randomisation with block sizes of 4 and 6. Randomisation will be stratified by Garden classification (Garden 1-2 vs. 3-4) to account for fracture displacement and by hospital of admission.

The operating surgeon will contact a central coordinator to perform the randomisation prior to surgery and will therefore know the allocated implant before entering the operating theatre.

Blinding Participants and care providers will be blinded to the allocated implant. A standardised description of the surgical procedure will be used. Treatment allocation will remain blinded during statistical analyses.

Data Collection Project staff will collect clinical data, CT scans, and radiostereometric X-rays and perform image analyses using AutoRSA. Screening will be conducted by the admitting physician. Baseline data will be collected during admission and entered directly into REDCap by project personnel.

Patient-reported outcome questionnaires will be distributed electronically via REDCap, with responses automatically uploaded to the database. Follow-up visits will take place in the outpatient clinic, where project personnel will complete and verify data entry.

Statistical methods Treatment groups will remain blinded during statistical analyses. Data distribution will be assessed and results presented accordingly. Continuous outcomes will be analysed using linear mixed-effects models, and categorical variables will be compared using χ² or Fisher's exact tests, as appropriate.

A p-value of \<0.05 will be considered statistically significant. Postoperative complication rates will be defined as the combined incidence of complications and reoperations. Mortality will be analysed using Cox regression. Statistical analyses and graphical presentation will be performed using STATA 18 (StataCorp).

02

Conditions studied

  • Femoral Neck Fractures
  • Internal Fixation; Complications
  • Hip Fractures

Keywords

  • femoral neck fracture
  • radiostereometric analysis
  • hip fracture
  • internal fixation
03

In context

Femoral Neck Fractures

207 studies on the registry are indexed under Femoral Neck Fractures; 40 are open to participants now.

This study's planned enrollment of 75 is below the median of 100 across 142 interventional studies indexed under Femoral Neck Fractures.

Browse Femoral Neck Fractures studies →

Lead sponsor

Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Femoral neck fracture (DS720)
  • Age 18-64 years
  • Ability to speak and read Danish
  • Willingness to participate

Exclusion criteria

Exclusion Criteria:

  • Pathological, basicervical or transcervical fracture
  • Clinical Frailty Scale ≥5, indicating mild to severe frailty prior to the fracture
  • Cognitive impairment that hinders
  • Previous fracture in the ipsilateral femur
  • Patients who are unwilling or incapable of following post-operative care instructions.
  • Comorbidities making the participant ineligible for internal fixation such as:

    • Material sensitivity, documented or suspected
    • Active or suspected latent infection, sepsis or marked local inflammation in or around the surgical area
    • Compromised vascularity, inadequate skin or neurovascular status
    • Compromised bone stock that cannot provide adequate support and/or fixation of the device due to disease, infection or prior implantation
    • Other physical, mental, medical or surgical conditions that would preclude the potential benefit of surgery.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Dynaloc

    Randomisation

    Device: Dynaloc implant

  • Active comparator
    Cannulated cancellous screws

    Randomisation

    Device: Cannulated cancellous screws

  • Active comparator
    Sliding hip screw

    Prospective cohort

    Device: Sliding hip screw

Interventions

  • DeviceDynaloc implant

    Internal fixation with Dynaloc implant

  • DeviceCannulated cancellous screws

    Internal fixation with two or three cannulated cancellous screws

  • DeviceSliding hip screw

    Internal fixation with a sliding hip screw

06

What researchers measure

Primary outcomes

  1. Static fracture migration

    Static non-weight bearing fracture migration in a supine set-up

    Time frame: 12 weeks

Secondary outcomes

  1. Static fracture migration

    Static non-weight bearing fracture migration in a supine set-up

    Time frame: 6 weeks

  2. New mobility score

    Assessment of gait. 0-9 points

    Time frame: Baseline, 6 weeks, 12 weeks

  3. Modified Harris Hip Score

    Measure of hip dysfunction. \<70 = poor result; 70-80 = fair, 80-90 = good, and 90-100 = excellent.

    Time frame: Baseline, 6 weeks, 12 weeks

  4. EQ-5D-5L

    Health related Quality of Life

    Time frame: Baseline, 6 weeks, 12 weeks

  5. Pain VRS

    Pain verbal rating scale 0-10

    Time frame: Baseline, 6 weeks, 12 weeks

  6. Reoperation

    Any secondary operation

    Time frame: 0-12 weeks

  7. Complication

    Any complication (non-union, avascular necrosis of the femoral head, fixation failure)

    Time frame: 0-12 weeks

  8. Mortality

    Death

    Time frame: 0-12 weeks

07

Study locations

3 of 4 sites recruiting
08

References and documents

Publications

  • Hansen MM, Petersen ET, Gundtoft PH, Jensen J, Stilling M, Ding M, Viberg B. Evaluation of femoral neck fracture migration after internal fixation with an angle stable implant compared with gold standard cannulated cancellous screws in young adults: study protocol for a clinical RCT using radiostereometric analysis. Trials. 2026 Feb 7;27(1):202. doi: 10.1186/s13063-026-09497-7. PubMed 41652608 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2027, 30 months after the start.

Of 63 non-industry interventional studies with no phase under Femoral Neck Fractures, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's planned 30 months is below that.

Counting every sponsor, half of 69 studies reached it within 46 months; a quarter within 25 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2024
First posted
Jul 26, 2024
StartActual
Jun 16, 2025
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2028
Last update
Jan 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06521671
Collaborators
Aarhus University Hospital, Region of Southern Denmark, Swemac Innovation AB, Gødstrup Hospital
Responsible party
Michaela Manalili Hansen (Medical Doctor, Odense University Hospital) — Principal investigator
First posted
Jul 26, 2024
Start date
Jun 16, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jan 27, 2026

Study contacts

Michaela Manalili Hansen, MD
Contact
michaela.manalili.hansen@rsyd.dk
+4560808836

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion